Tyrphostin B42 for COVID-19

 Tyrphostin B42 has been reported as potentially beneficial for COVID-19 in the following study.
COVID-19 involves the interplay of 350+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 10,000+ potential treatments. c19early.org analyzes 200+ treatments. We have not reviewed tyrphostin B42 in detail.
Garcia et al., Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication, Cell Reports, doi:10.1016/j.celrep.2021.108940